BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Johnson & Johnson (JNJ) Unit Gets Priority Revenue for Simeprevir NDA


5/14/2013 7:37:31 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Johnson & Johnson (JNJ) unit Janssen Research and Development LLC said the U.S. Food and Drug Administration has granted priority review to its new drug application for simeprevir, its investigational treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease. Simeprevir is an investigational NS3/4A protease inhibitor administered as a 150-milligram capsule once daily with pegylated interferon and ribavirin. Hepatitis C virus is a blood-borne infectious disease of the liver that affects about 3.2 million people in the U.S. The FDA grants priority review to medicines that may offer major advances in care or provide a treatment option where no adequate therapy exists.

Help employers find you! Check out all the jobs and post your resume.


Read at Fox News
Read at News-Medical
Read at nj.com
Read at Pharma Times [Free Reg Req'd]

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES